Healthcare Sales & Marketing Network News: Boston Biomedical

Searching News Database: Boston Biomedical

HSMN NewsFeed - 1 Jul 2020
Sumitomo Dainippon Pharma Oncology Announces Its Formation Through Merger of Tolero and Boston Biomedical
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 20 Mar 2020
Biostage Announces IND Approval from FDA for its Lead Product Candidate Cellspan(TM) Esophageal Implant
Devices Regenerative Medicine FDA

HSMN NewsFeed - 14 Nov 2016
Boston Biomedical Announces Orphan Drug Designation for Napabucasin in Pancreatic Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 25 Jan 2016
Boston Biomedical's Investigational Cancer Stem Cell Pathway Inhibitor, Napabucasin (BBI608), Featured at the ASCO 2016 Gastrointestinal Cancers Symposium
Biopharmaceuticals Oncology Gastroenterology

HSMN NewsFeed - 1 Mar 2012
Dainippon Sumitomo Pharma Co., Ltd. to Acquire Boston Biomedical, Inc. for up to $2.63 Billion; Acquisition Includes a World-Leading Pipeline Targeting Cancer Stem Cells
Biopharmaceuticals Oncology Mergers & Acquisitions

Return to NewsFeed

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.